Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 D-Pharm Begins Ukraine Stroke Trial | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

D-Pharm Begins Ukraine Stroke Trial

Will test THR-18 in conjunction with tPA

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

D-Pharm Ltd. has received approval from regulatory authorities in the Ukraine to commence a Phase IIa clinical study of THR-18, to be given with the clot buster drug tissue plasminogen activator (tPA), in patients with acute ischemic stroke. THR-18 is a synthetic therapeutic peptide derived from plasminogen activator inhibitor-1 (PAI-1).

This is a double-blind, placebo-controlled, escalating single-dose trial to assess the safety, pharmacokinetics and pharmacodynamics of THR-18 given with tPA to patients with acute ischemic stroke. The study will enroll 30 patients divided into three escalating dose groups, each group with an active and placebo arm. The study will be performed at a single site in Kharkov, Ukraine. THR-18 has successfully completed a Phase I clinical study in healthy volunteers.

Tissue plasminogen activator is approved for treatment of myocardial infarction, pulmonary embolism and it is the only drug approved by the FDA and EMA for treatment of acute ischemic stroke. However, in stroke, tPA is used, on average, in less than 5% of patients and within a narrow time window, due to the risk of life-threatening adverse effects, in particular, intra-cerebral hemorrhage (ICH). Results from a survey of neurologists and payors suggest that as many 90% of patients treated with tPA would also receive treatment with THR-18 (if approved). D-Pharm assumed responsibility for THR-18 development in 2012 when the company acquired the clinical stage company Thrombotech Ltd.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics